Loncar Cancer Immunotherapy ETF (CNCR), An ETF that invest in Immunotherapy
ABOUT THE FUND
The Loncar Cancer Immunotherapy ETF, An ETF that invest in Immunotherapy, seeks to track the LCINDX index. It is made up of a basket of companies that develop therapies to treat cancer by harnessing the body’s own immune system. Immunotherapy is a transformational field within the biotechnology space that is expected to become the foundational treatment for cancer over the next ten years. A sector ETF focusing on a unique technology like cancer immunotherapy allows investors to focus on interest areas more precisely than broad indices. LCINDX is an equal-weighted index containing both large pharmaceutical and growth-oriented biotechnology companies that are leading in this approach.
Click to enlarge
INVESTMENT RATIONALE
Cancer immunotherapy has become an important sector in the biotechnology space and is changing the way many cancers are treated. While traditional medicines like chemotherapies often give cancer a broad punch, the benefit of using immunotherapy is derived from the immune system’s dynamic nature and the way it can more precisely be tailored to fight a patient’s disease. Some immunotherapies have exhibited uncommon results in clinical trials.
Today, many new classes of cancer immunotherapies are being developed. These include checkpoint inhibitors (which are already FDA approved for melanoma and lung cancer), cancer vaccines, bispecific antibodies, and chimeric antigen receptor (CAR-T) technologies. With this distinct sector focus, the fund aims to help investors capture a growth area of the biotechnology space. At the same time, it will support this method of treating cancer by providing capital to public companies that are leaders in the space.
Click to enlarge
* Fund holdings and allocations are subject to change at any time and should not be interpreted as an offer of these securites.
INDEX PROVIDER
Loncar Investments LLC was founded by noted independent biotech investor and analyst Brad Loncar. Mr. Loncar regularly provides his unique insight and analysis on this market segment to the investment community via a variety of publishing platforms. Through Loncar Investments LLC, Mr. Loncar incorporates his extensive research into biotech companies and technologies to develop indexes focused on precise investment opportunities.
Click to enlarge
Disclaimer
The Fund’s investment objectives, risks, charges and expenses must be considered carefully before investing. The summary and statutory prospectuses contain this and other important information about the investment company, and it may be obtained by calling 800-617-0004. Read it carefully before investing. Investing involves risk, including the possible loss of principal. Shares of any ETF are bought and sold at market price (not NAV), may trade at a discount or premium to NAV and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. The Fund will invest in immunotherapy companies which are highly dependent on the development, procurement and marketing of drugs and the protection and exploitation of intellectual property rights. A company’s valuation can also be greatly affected if one of its products is proven or alleged to be unsafe, ineffective or unprofitable. The costs associated with developing new drugs can be significant, and the results are unpredictable. The process for obtaining regulatory approval by the U.S. Food and Drug Administration or other governmental regulatory authorities is long and costly and there can be no assurance that the necessary approvals with be obtained and maintained.
